ACADIA Pharmaceuticals Inc. (ACAD) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Core Insights - ACADIA Pharmaceuticals aims to become a leading company in neurological and rare diseases, focusing on delivering meaningful innovations to underserved patients [2][3] Neurological Franchise - The momentum of NUPLAZID is expected to continue driving growth this year and beyond [3] - The company is advancing several pipeline candidates, including a new 5-HT2A agonist, remlifanserin (formerly ACP-204) [3] - Ongoing Phase II programs include ACP-211, a deuterated R-ketamine for major depressive disorder, and potential expansions into essential tremor with ACP-711 and tardive dyskinesia with ACP-271 [3]